Phase 2 trial of talampanel, a glutamate receptor inhibitor, for adults with recurrent malignant gliomas Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Benzodiazepines
  • Brain Neoplasms
  • Glioma
  • Receptors, AMPA

abstract

  • : Talampanel was well-tolerated but had no significant activity as a single agent in unselected recurrent malignant gliomas. Cancer 2010. Published 2010 by the American Cancer Society.

publication date

  • April 2010

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC2846997

Digital Object Identifier (DOI)

  • 10.1002/cncr.24957

PubMed ID

  • 20143438

Additional Document Info

start page

  • 1776

end page

  • 82

volume

  • 116

number

  • 7